Apricus Biosciences (NASDAQ:APRI)

CAPS Rating: 2 out of 5

A pharmaceutical and medical technology company, which conducts research and development both domestically and abroad on proprietary pharmaceutical products.

Results 1 - 13 of 13

Recs

0
Member Avatar qualatech (74.69) Submitted: 10/23/2013 2:55:06 PM : Outperform Start Price: $2.03 APRI Score: -27.12

Just received approval for phase testing of ED drug in Europe. Much insider ownership. Little debt. Just registered 1M shares. Management knows something the street doesnt.

Recs

1
Member Avatar zzlangerhans (99.82) Submitted: 3/22/2013 1:52:03 AM : Outperform Start Price: $2.48 APRI Score: -55.25

It seems that the coast is clear for Vitaros and Femprox hype to start moving Apricus back into the 3's. Of course, this would be a very risky trade in real life as I believe Vitaros will prove to be uncompetitive with other products for erectile dysfunction and Femprox is unlikely to ever be commercialized. But with PrevOnco and MycoVa quiescent, the pipeline components most susceptible to bad news aren't likely to interfere with a strong dose of sex drug hype I'm expecting within the next few months.

Recs

0
Member Avatar thedrew1125 (57.42) Submitted: 2/23/2013 10:58:41 PM : Outperform Start Price: $2.70 APRI Score: -62.74

Gotta give some love to local San Diego companies. That easily-absorbed molecule that they put in their topical treatments will hopefully get some more use.

Recs

0
Member Avatar etra (< 20) Submitted: 11/17/2012 4:33:26 PM : Outperform Start Price: $2.18 APRI Score: -61.44

At present most players of APRI stock buy and then sell almost on a daily basis.The company should convince investment groups that future earnings should enable them to carry the price to $5.00 ..

Recs

0
Member Avatar acts20 (34.05) Submitted: 3/25/2012 5:49:37 PM : Outperform Start Price: $2.96 APRI Score: -78.59

Room to roam

Recs

0
Member Avatar cubanstockpicker (20.90) Submitted: 8/25/2011 6:22:17 PM : Outperform Start Price: $3.97 APRI Score: -121.60

Name reputation alone makes sure founder gets only the best students and the brightest researchers to then turn over the best and brightest products. To then be bought out for more than enough to make us the (you get the idea) profit.

Recs

0
Member Avatar Allstar13913 (99.82) Submitted: 7/30/2011 10:15:59 PM : Underperform Start Price: $3.14 APRI Score: +87.10

Company that is using data-mining to hopefully show a failed drug has potential.

http://www.thestreet.com/_yahoo/story/11169285/1/biotech-data-mining-comes-up-empty.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA

Recs

0
Member Avatar josh28105 (< 20) Submitted: 2/23/2011 5:25:46 AM : Outperform Start Price: $5.09 APRI Score: -110.83

This stock has a lot of good things coming out.

Recs

0
Member Avatar THEMATHISNEAR (< 20) Submitted: 2/17/2011 10:15:30 AM : Underperform Start Price: $4.33 APRI Score: +112.70

Shorting a bunch of rickety-financed biotechs that have run up for no reason. Yes, I expect one to pop, and don't know which one, but I expect that most will fail outright, and the group as a whole will fail to match the S&P.

Recs

0
Member Avatar dmacin (< 20) Submitted: 2/16/2011 9:52:24 PM : Outperform Start Price: $4.20 APRI Score: -102.17

Seems to be moving

Recs

0
Member Avatar dustinmoh6 (< 20) Submitted: 11/23/2010 10:23:07 PM : Outperform Start Price: $3.22 APRI Score: -108.49

Apricus's unique NexACT technology could prove to be very valuable, both from their own drugs and out-licensing to other companies to use. The company has a large arsenal of drugs covering a wide array of health issues. More importantly Apricus's first approved drug, Vitaros, could be a huge winner in the large ED market. It looks as if the company has turned a corner.

Recs

0
Member Avatar dustinm06 (< 20) Submitted: 11/23/2010 9:39:05 AM : Outperform Start Price: $3.49 APRI Score: -111.44

Apricus retains a very innovative core technology called NexACT. This can be blended with already known and effective treatments. NexACT helps these compounds be better absorbed in the body and allows multiple routes of delivery. With an already approved drug, Vitaros, the company has a proven and clinically validated technology it will leverage and monetize.

Recs

1
Member Avatar spikenail (< 20) Submitted: 6/13/2007 12:21:43 PM : Outperform Start Price: $31.20 APRI Score: -127.05

Biotech....pharma tech.....these are the companis that are making all the money in the pharma sector.

Results 1 - 13 of 13

Featured Broker Partners


Advertisement